Is heat stability of vaccines really possible?

Here’s a problem most people never think about. A vaccine gets manufactured in a facility in Pune or Hyderabad. It then needs to reach a child in a remote village in Jharkhand, or a clinic in rural Nigeria, or a health post in the highlands of Papua New Guinea. Between the factory and that child’s arm, the vaccine passes through warehouses, trucks, aircraft holds, motorbike panniers, and health worker cooler bags — sometimes over several days.

If the temperature breaks at any point, the vaccine may be ruined. And nobody can tell by looking at it. This is the real-world challenge of vaccine stability — and it’s one of the most important, least-discussed problems in global public health.

What Vaccine Stability Actually Means

Vaccine stability refers to how well a vaccine holds its potency and safety over time under real-world storage and transport conditions.

Every vaccine contains active biological components — proteins, live attenuated viruses, toxoids, or polysaccharides. These are fragile. Expose them to heat, freeze them when they shouldn’t be frozen, shake them too roughly, or keep them past their shelf life — and they degrade.

A degraded vaccine doesn’t protect. Worse, it doesn’t announce its failure. The health worker administering it doesn’t know. The patient receiving it doesn’t know. The child goes home with a false sense of protection that was never actually delivered.

This is why vaccine stability isn’t a technical detail for scientists to worry about in isolation. It has direct consequences for every immunisation program in the world.

The Problem with Vaccine Storage Temperature

Most vaccines need to be kept between 2°C and 8°C. That’s the standard refrigerator range. Some vaccines — like live oral polio vaccine and varicella — are even more demanding and need to be kept frozen.

Maintaining vaccine storage temperature sounds simple enough in a well-resourced setting. You have a reliable cold room, regular electricity, calibrated refrigerators, and trained staff monitoring temperature logs. Easy.

In low- and middle-income countries, none of those things can be taken for granted. Power cuts last for hours. Refrigerators break down. Health workers in remote areas transport vaccines in ice-packed cooler boxes that warm up faster than expected. A village health post that runs out of ice on a 40°C afternoon is a crisis in slow motion.

Even in wealthy countries, vaccine storage temperature failures happen regularly. Studies from the United States, UK, and Australia have documented instances where refrigerator temperatures in clinics drifted outside the safe range — sometimes for hours, sometimes for days — without staff noticing until equipment was checked.

What Is the Vaccine Cold Chain?

The vaccine cold chain is the system — equipment, people, procedures, and monitoring — that keeps vaccines at the right temperature from manufacture to administration.

It starts at the production facility and runs through international and national warehouses, regional distribution centres, district cold stores, primary health centres, and finally the point of immunisation.

The components of the vaccine cold chain include:

• Cold rooms and walk-in freezers at national and regional level for bulk storage
• Refrigerators and freezers at district and health facility level
• Vaccine carriers and cold boxes for transport to outreach sites
• Ice packs and dry ice for maintaining temperature during transport
• Temperature monitoring devices — electronic loggers, fridge tags, and vaccine vial monitors (VVMs) — that track exposure to temperature excursions

A vaccine vial monitor is a small indicator placed on each vial or bottle that changes colour if the vaccine has been exposed to excessive heat for too long.

Heat Stable Vaccines: Why They Matter

Heat stable vaccines are ones that can tolerate higher temperatures — sometimes 37°C or even 40°C — for a defined period without losing their protective effect.

Not all vaccines are equally fragile. Some are naturally more stable than others. Hepatitis B vaccine, for example, is relatively heat stable compared to live vaccines like oral polio or measles. This affects how they’re handled, stored, and distributed.

But most traditional vaccines have limited heat stable profiles. They were formulated for cold chain delivery in well-resourced settings. As immunisation programs pushed into more remote areas — places where cold chains are genuinely difficult to maintain — the limitations of these formulations became a major barrier.

Heat stable vaccines address that barrier directly. A vaccine that can survive a week at 37°C doesn’t need a functioning refrigerator at every distribution point.

Thermostable Vaccines: What Science Is Doing About Heat Sensitivity

Thermostable vaccines are specifically formulated or processed to remain effective at elevated temperatures for extended periods.

Lyophilisation (freeze-drying) is one of the oldest methods. Removing water and reconstituting just before use makes the dry formulation significantly more stable. Measles, BCG, and yellow fever vaccines are already lyophilised — which is partly why they tolerate temperature variation better than liquid formulations.

Vitrification is newer. The vaccine is suspended in a glassy sugar matrix that protects active components from heat degradation. Some formulations have demonstrated stability at 37°C for six months or more.

Microarray patches — dissolving microneedle patches with active ingredients embedded in solid polymer tips — are inherently more stable than liquid formulations. Several candidates are in clinical trials.

The thermostable vaccines field has also benefited from mRNA research. Scientists are working on mRNA formulations that survive at refrigerator temperatures rather than the ultra-cold conditions COVID-19 vaccines initially required.

Why This Matters for Global Immunisation

WHO estimates that up to half of all vaccines are wasted globally every year. Temperature failures during storage and transport are one of the leading causes.

In countries with fragile cold chains, wastage is higher and consequences are more severe. Coverage statistics may look acceptable on paper while hiding the fact that a large proportion of administered doses offered no real protection.

Thermostable vaccines and improved vaccine cold chain systems together offer the most realistic path to closing that gap. Neither is sufficient alone. Cold chain improvement takes years of investment and local capacity building. Heat stable vaccines provide a parallel track — reaching communities where cold chain improvement won’t arrive fast enough.

For health workers operating without reliable electricity and for governments trying to meet immunisation targets on tight budgets, vaccine stability research isn’t abstract.

Current State and What’s Coming

Several heat stable vaccines are already in use. The meningitis A vaccine used across Africa’s meningitis belt — MenAfriVac — was approved for a controlled temperature chain, meaning it could be stored at up to 40°C for four days at the end of the cold chain.

The typhoid conjugate vaccine, rotavirus vaccines, and some formulations of HPV vaccine have also shown improved thermostability profiles compared to older versions. Progress is real, if uneven.

Research pipelines from organisations like PATH, the Serum Institute, IAVI, and various academic groups are actively working on next-generation formulations with substantially better vaccine storage temperature tolerance.

FAQs About Vaccine Stability and Cold Chain

1. What happens to a vaccine if it’s exposed to heat above the recommended storage temperature?

The active biological components degrade. Proteins unfold. Live viruses lose infectivity. Toxoids lose their ability to stimulate an immune response. The extent of damage depends on how high the temperature was and for how long. A brief excursion to 10°C for a few hours may cause minimal harm.

2. What is a vaccine vial monitor and how does it help?

A vaccine vial monitor (VVM) is a small heat-sensitive label attached to each vaccine vial. It contains a chemical that darkens with cumulative heat exposure over time. When the inner square becomes as dark as or darker than the outer ring, the vaccine should not be used. VVMs are one of the most practical tools in the vaccine cold chain because they give health workers a direct, real-time indicator of heat exposure at the point of use — no equipment, no electricity required.

3. Are there vaccines that don’t need refrigeration at all?

Not yet at scale, but some thermostable vaccines formulations can tolerate elevated temperatures for defined periods. MenAfriVac, the meningitis A vaccine, is approved for a controlled temperature chain — storage at up to 40°C for up to four days. Oral cholera vaccines and some rotavirus formulations also have improved thermostability.

4. Why can’t we just make better cold chains everywhere instead of developing heat stable vaccines?

Both approaches are needed. Cold chain infrastructure improvement is essential and ongoing, but it takes significant investment and years of capacity building. Many of the areas with the worst immunisation coverage are exactly the areas where building reliable cold chains is hardest — remote geography, unreliable power, limited trained staff. Heat stable vaccines provide coverage in places and circumstances where cold chain improvement alone won’t arrive fast enough.

5. What is the difference between thermostable and heat stable vaccines?

The terms are often used interchangeably and there’s no strict regulatory distinction. Generally, thermostable vaccines refers to formulations that have been specifically engineered or processed for improved temperature tolerance — often through lyophilisation, vitrification, or encapsulation. Heat stable vaccines is a broader term that includes vaccines that are naturally more tolerant of temperature variation as well as engineered formulations.